Kennedy was one of the first Curated by Alan Blum, MD Professor and Endowed Chair in Family Medicine Director, Center for the Study of Tobacco and Society College of Community Health Sciences The University of Alabama School of Medicine, Tuscaloosa Designed by Bryce Callahan Undergraduate student majoring in computer engineering Center for the Study of Tobacco and Society College of Community Health Sciences The University of Alabama School of Medicine, Tuscaloosa Acknowledgments *Gregory Connolly DMD MPH Former Director of the Massachusetts Tobacco Control Program, 1985-2004, for donating the video of the ABC-TV news report on the opening day of the First World Conference on Smoking and Health, September 11, 1967 Paul Goldberg Editor and Publisher, The Cancer Letter , for providing insights into the history of efforts by the federal government to reduce the toll taken by cancer

A recent review of drug options for tobacco dependence noted: The pharmacological effect of nicotine plays a crucial role in tobacco addiction, and therefore pharmacotherapy is important to address this component of tobacco dependence in order to improve success rates. 1 A global market of around 650 million potential customers is an alluring prospect for pharmaceutical companies, yet there are just three major options for drug-aided smoking cessation: various nicotine replacement therapies and the drugs bupropion and varenicline
Seddon S, Russell R
Public health researchers have expressed concern that new nicotine-containing products, like light cigarettes in the past, contain hidden health risks, are used to recruit youth consumers rather than facilitate smoking cessation, and perpetuate addiction among dual users. Juul, whose potent nicotine salt formula and aggressive youth marketing on social media led to a teen vaping epidemic in the United States and inspired Philip Morris parent company Altria to acquire a 35% stake in the company for US$12.8 billion, stands as a stark cautionary tale